ArticleFrontiers in medicine2026
LDAR shows more consistent prognostic performance than other albumin-derived indices for 28-day ICU mortality in critically ill patients with urosepsis: evidence from a dual-cohort retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Urosepsis remains a leading cause of ICU mortality. Albumin-derived composite indices, which integrate nutritional, inflammatory, and metabolic parameters, hold prognostic promise; however, their comparative performance has not been directly assessed. Methods: We conducted a dual-cohort retrospective study using MIMIC-IV ( Results: In the derivation cohort, logLDAR, RAR, TAR, AGAR, and UAR were independently associated with 28-day ICU mortality in fully adjusted models (HRs = 1.292, 1.147, 1.136, 1.074, and 1.013, respectively; all Conclusion: Among the six albumin-derived indices, logLDAR demonstrated the most consistent and generalizable prognostic performance for 28-day ICU mortality in urosepsis, reflecting both tissue hypoxia and nutritional-inflammatory depletion, and remained robust under competing-risk adjustment. logLDAR may serve as a simple bedside biomarker for early risk stratification; however, prospective studies are warranted to determine whether interventions targeting its underlying pathways can improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.